Navigation Links
Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
Date:7/21/2010

GREENWOOD VILLAGE, Colo., July 21 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE) today announced the initiation of a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus.

Ampio Pharmaceuticals has completed a formal agreement with St Michael's Hospital, Toronto, Canada as a final step for ethics board approval which is expected in the next few days.  "We are very excited to be commencing this trial and pending the final approval of the ethics board we will commence patient recruitment in the next weeks," stated Don Wingerter, CEO of Ampio Pharmaceuticals. Chief Scientific Officer, Dr. David Bar-Or added, "After accumulating in vitro and animal data, it is gratifying to begin treating patients for this debilitating disease."

Diabetic macular edema and diabetic retinopathy are complications of diabetes mellitus that occur in approximately one third of patients 10 years after the onset of diabetes and are rapidly growing causes of blindness worldwide. There is currently no effective oral medication to treat diabetic macular edema or diabetic retinopathy. Optina™ is a repurposed oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina™ to significantly reduce diabetic macular edema in patients.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near-term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs.

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

Contact: Redwood Consultants, LLC Tel: +1 415-884-0348


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioMEMS Completes CHAMPION Clinical Trial Study
2. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
3. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
4. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
5. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
6. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
7. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
8. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
9. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
10. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 The U.S. Food and Drug Administration ... Constipation (CIC) in adult patients. "No one ... said Julie Beitz , M.D., director of the Office ... Evaluation and Research. "With the availability of new therapies, patients ... their condition." ...
(Date:1/19/2017)... -- Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical ... new additions to its senior leadership team: W. ... Daniel Geffken as interim Chief Financial Officer. ... Pharm.D. has been promoted to Chief Clinical Development Officer. ... and Daniel to our management team, as both will ...
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have ... are efficient when clearing large amounts of snow, but they can be dangerous when used ... Consumer Product Safety Commission for the proper use of snow blowers:, , ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote ... recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. ... to RMT technology that delivers HD, dynamic, streaming ultrasound images and video to ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... certified dermatologist by the American Board of Dermatology and fellowship trained Mohs and ... the National Institutes of Health, Dr. Li completed his internship in internal medicine ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Students interested ... Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship and have ... competition begins Feb. 1, and the deadline is May 31, with the winner announced ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) officials today announced a ... the Network’s programs and services in the greater Pittsburgh region. Starting January 23, patients ... offered one for that same afternoon. , AHN is the first ...
Breaking Medicine News(10 mins):